Company Focus
Bristol Myers Squibb
Latest Bristol Myers Squibb News
Biotechnology
Switzerland-based Philochem and Bristol Myers Squibb radiopharma subsidiary RayzeBio have announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. 11 June 2025
Related News
Insights
Company Spotlight
A private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension.
Latest News & Features of interest to Bristol Myers Squibb
Biotechnology
Psychedelic medicines company Compass Pathways was trading 46% lower midday Monday. 23 June 2025
Biotechnology
Philadelphia, USA-based Medicus Pharma today announced the appointment of Andrew Smith as chief operating officer (COO). 23 June 2025
Biotechnology
The Alliance for Regeneration Medicine (ARM), a trade group that represents more than 400 members companies across 25 countries, including emerging and established biotech firms, has taken aim at the powers that be in US healthcare. 23 June 2025
Pharmaceutical
US pharma giant Merck & Co today announced positive top-line results from the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. 23 June 2025
Pharmaceutical
US biopharma Vertex Pharmaceuticals and Japanese drugmaker Ono Pharmaceutical have announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. 23 June 2025
Pharmaceutical
Swiss drugmaker Idorsia today announced that Simcere Pharmaceuticals (HK: 2096) has received approval for Quviviq (daridorexant) from the Chinese National Medical Products Administration for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep, with no psychotropic drug control labeling. 23 June 2025
Pharmaceutical
US drugmaker Vertex Pharmaceuticals has announced simultaneous presentation and publication of updated data from the Phase I/II portion of the Phase I/II/III FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). 23 June 2025
Biotechnology
Swiss pharma giant Roche has released encouraging results from the Phase III SUNMO study showing Lunsumio (mosunetuzumab) administered subcutaneously in combination with Polivy (polatuzumab vedotin), delivered a seismic update in aggressive lymphoma therapy. 23 June 2025
Pharmaceutical
Danish drugmaker Novo Nordisk has released fresh clinical data on two of its lead investigational assets, seeking to bolster its strong position in obesity while moving to challenge in rare blood disorders. 23 June 2025
Pharmaceutical
Armed with an asset that could be an improvement on Pfizer’s blockbuster smoking cessation drug Chantix/Champix (varenicline), Achieve Life Sciences (Nasdaq: ACHV) has confidence in its prospects of addressing the global smoking health and nicotine addiction epidemic. 23 June 2025
Latest In Brief for Bristol Myers Squibb
Biosimilars
The European Medicines Agency’s human medicines committee (CHMP) adopted positive opinions for six biosimilar medicines at its June meeting. 20 June 2025
Latest Relevant Ones To Watch News
Notable research news last week included Sarepta Therapeutics reporting another death associated with a trial of its Duchenne muscular dystrophy drug Elevidys. On the M&A front, US pharma major Eli Lilly last Tuesday announced it is to acquire Verve Therapeutics for up to $1.3 billion, along with its VERVE-102. Regulatory news saw the US Food and Drug Administration (FDA) announce a new voucher program aimed at enhancing the health interests of Americans. The FDA also approved Incyte’s Monjuvi for relapsed or refractory follicular lymphoma (LF). 22 June 2025
17 June 2025
16 June 2025
12 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze